Vitiligo
☆ AI Dermatology — Free Service
En los resultados de 2022 del Stiftung Warentest de Alemania, la satisfacción del consumidor con ModelDerm fue sólo ligeramente inferior que con las consultas de telemedicina pagadas.
En los resultados de 2022 del Stiftung Warentest de Alemania, la satisfacción del consumidor con ModelDerm fue sólo ligeramente inferior que con las consultas de telemedicina pagadas.
Vitíligo no segmentario (Non-segmental vitiligo)
El vitíligo de los dedos es más difícil de tratar que en otras áreas. Además de ser estéticamente antiestético, el vitíligo es una condición normal y no contagiosa. En dermatología, el tratamiento más eficaz es la fototerapia o el láser excimer, aplicado 2‑3 veces por semana durante al menos un año. Si no puede acudir al hospital con frecuencia por motivos económicos o por falta de tiempo, puede probar una máquina de fototerapia aprobada para uso doméstico.
Vitíligo en la mano
relevance score : -100.0%
ReferencesEl vitiligo es un trastorno cutáneo frecuente que produce manchas blancas en la piel por la pérdida de melanocitos. Estudios recientes indican que se trata de una enfermedad autoinmune. Aunque a menudo se percibe como un problema cosmético, puede afectar profundamente el bienestar mental y la vida cotidiana. En 2011, los expertos clasificaron un tipo llamado vitiligo segmental como una entidad distinta de los demás.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Los pacientes con vitíligo activo disponen de varias opciones de tratamiento, como glucocorticoides sistémicos, fototerapia e inmunosupresores sistémicos. Los pacientes con vitíligo estable pueden encontrar alivio con corticosteroides tópicos, inhibidores de la calcineurina tópicos, fototerapia y procedimientos de trasplante. Los avances recientes en la comprensión de los procesos subyacentes del vitíligo han conducido al desarrollo de terapias dirigidas. Actualmente, los inhibidores de JAK son los más prometedores, ya que ofrecen buena tolerabilidad y resultados funcionales, aunque conllevan el riesgo de activar infecciones latentes y de presentar efectos secundarios sistémicos, similares a los de otros agentes inmunosupresores. La investigación en curso tiene como objetivo identificar citocinas clave involucradas en el desarrollo del vitíligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). El bloqueo de estas citocinas ha demostrado ser prometedor en modelos animales y en algunos pacientes. Además, se están llevando a cabo investigaciones sobre miRNA‑based therapeutics y adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
No existe una cura conocida para Vitiligo. En las personas con piel clara, lo único que normalmente se recomienda es el uso de protector solar y maquillaje. Otras opciones de tratamiento pueden incluir cremas con esteroides o fototerapia.
○ Tratamiento
#Phototherapy
#Excimer laser
#Tacrolimus ointment